German Diabetes Center
Düsseldorf, North Rhine-Westphalia, 40225, Germany
Location status: Recruiting
Location contact
Michael Roden, Prof., MD
CONTACT
0049211-3382 ext. 201
Sabine Kahl, MD
CONTACT
0049211-3382 ext. 698
NCT Number: NCT01477957
The purpose of this study is:
1. To explore to what extent insulin sensitivity, energy metabolism and ectopic lipid storage can be improved by bariatric surgery 2. To explore to what extent hepatic and muscular disorders of energy metabolism occur in patients with obesity (degree 2-3) 3. To explore whether the steato liver occurring in patients with obesity (degree 2-3) is associated with the degree of liver inflammation
Interested in participating?
Request Info20 year–70 year
All sexes
Observational
Düsseldorf, North Rhine-Westphalia, 40225, Germany
Location status: Recruiting
Michael Roden, Prof., MD
CONTACT
0049211-3382 ext. 201
Sabine Kahl, MD
CONTACT
0049211-3382 ext. 698
Insulin resistance strongly relates to ectopic lipid deposition in skeletal muscle and the liver, which correlate with insulin resistance. Lipid metabolites accumulating in skeletal muscle and the liver are thought to impair insulin signalling and thereby reduce glucose uptake and glycogen storage. Insulin resistant humans frequently present with decreased mitochondrial function in skeletal muscle which might contribute to lipid accumulation and the development of insulin resistance. Metabolic dysfunction-associated steatotic liver disease comprises steatosis, steatohepatitis and cirrhosis. MASLD correlates with insulin resistance, increased risk for cardiovascular diseases and type 2 diabetes. The mechanisms leading from steatosis to steatohepatitis and insulin resistance in the liver are yet unclear. Bariatric surgery aims at profound reduction of body weight. Also, it frequently and rapidly leads to normalization of glucose tolerance even before the onset of body weight reduction. The underlying mechanisms are yet unclear. In this study we aim to explore the mechanisms underlying the onset of insulin resistance and steatohepatitis in patients with steatosis and to identify the mechanisms leading to improved glucose tolerance in humans after bariatric surgery. We test the following hypotheses: increased lipid availability leads to (i) increased lipid oxidation and oxidative stress (ii) accumulation of lipid metabolites that impair insulin signalling (iii) bariatric surgery improves insulin sensitivity by increasing lipid oxidation.
This study will contribute to the understanding of MASLD and will help to identify new targets for the therapy of diabetes.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
biliopancreatic diversion, gastric banding, gastric sleeve resection
Other names: bariatric surgery
Time frame: 5 years
whole body substrate oxidation, ex vivo mitochondrial function via measurement of high resolution respirometry and in vivo mitochondrial function via measurement of ATP production
Time frame: 5 years
body weight and body composition before and after bariatric surgery
Time frame: 5 years
Whole body glucose uptake and endogenous glucose production as measure of skeletal muscle and hepatic insulin sensitivity
Contact information is provided by the study sponsor or research team.
German Diabetes Center
Other
The Effect of Bariatric Surgery on Insulin Sensitivity and Energy Metabolism in Obesity Grade 2 -3
Acronym: BARIA-DDZ
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06138821
Body Weight, Body Weight Changes
Boston, Massachusetts, United States
View Trial DetailsNCT02861781
Body Weight, Diabetes Mellitus
Montpellier, France
View Trial DetailsNCT05165706
Body Weight, Diabetes Mellitus
Stanford, California, United States
View Trial DetailsNCT00445627
Body Weight, Diabetes Mellitus
Bethesda, Maryland, United States
View Trial Details